Senior Convertible Note Purchase Agreement Dated as of April 9, 2020Senior Convertible Note Purchase Agreement • April 9th, 2020 • Scynexis Inc • Pharmaceutical preparations • New York
SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of April 9, 2020 (the “Closing Date”), among SCYNEXIS, Inc., a Delaware corporation, as Issuer (the “Company”), and Puissance Life Science Opportunities Fund VI (the “Investor”).
ANTERIOS, INC. SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT OCTOBER10, 2014Senior Convertible Note Purchase Agreement • March 31st, 2015 • Anterios Inc • Pharmaceutical preparations • New York
THIS SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT (“Agreement”) is made as of October 10, 2014, by and among Anterios, Inc., a Delaware corporation (the “Company”), and the lenders (each individually a “Lender,” and collectively the “Lenders”) named on the Schedule of Lenders attached hereto (the “Schedule of Lenders”). Capitalized terms not otherwise defined in this Agreement shall have the meanings ascribed to them in Section 1 below.
SECOND AMENDMENT TO SENIOR CONVERTIBLE NOTE Purchase Agreement April 13, 2020Senior Convertible Note Purchase Agreement • April 14th, 2020 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment to Convertible Note Purchase Agreement (this “Amendment”) is entered into as of the date first written above by and among Coherus BioSciences, Inc., a Delaware corporation (the “Company”) and the undersigned holders (each a “Holder” and collectively, the “Holders”) that are parties to that certain Senior Convertible Note Purchase Agreement, dated as of February 29, 2016, by and among the Company and the holders named therein (as amended, the “Note Purchase Agreement”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Note Purchase Agreement.
TRANSDEL PHARMACEUTICALS, INC. SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENTSenior Convertible Note Purchase Agreement • April 8th, 2010 • Transdel Pharmaceuticals Inc • Pharmaceutical preparations • California
This Senior Convertible Note Purchase Agreement (the “Agreement”) is made as of this ___day of April 2010 by and between Transdel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the undersigned purchasers as listed on Schedule A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).
Exhibit 10.20 SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT dated as of June 11, 1997Senior Convertible Note Purchase Agreement • July 24th, 1998 • 24/7 Media Inc • Services-advertising • New York
Amendment Dated as of March 25, 2016 to Senior Convertible Note Purchase AgreementSenior Convertible Note Purchase Agreement • May 9th, 2016 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
Reference is made to that certain Senior Convertible Note Purchase Agreement (the “Agreement”), dated as of February 29, 2016, among Coherus BioSciences, Inc., a Delaware corporation (the “Company”), the Guarantors named therein and the Investors named therein, and the 8.2% Senior Convertible Notes due 2022 (the “Notes”) issued pursuant to the Agreement. Capitalized terms used in this Amendment without definition have the respective meanings given to them in the Agreement.
COHERUS BIOSCIENCES, INC., as Issuer, the Guarantors from time to time party hereto, as Guarantors AND HealthCare Royalty Partners III, L.P., MX II Associates LLC, KMG Capital Partners, LLC AND KKR Biosimilar L.P., each as an Investor Senior...Senior Convertible Note Purchase Agreement • February 29th, 2016 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of February 29, 2016 (the “Closing Date”) among Coherus BioSciences, Inc., a Delaware corporation, as Issuer (the “Company”), InteKrin Therapeutics Inc., a Delaware corporation, and Coherus Intermediate Corp., a Delaware corporation, as the Guarantors (as defined below), and HealthCare Royalty Partners III, L.P., MX II Associates LLC, KMG Capital Partners, LLC and KKR Biosimilar L.P. (each, an “Investor,” and, collectively, the “Investors”).
